CEO’s Big Buy of Compass Pathways Shares Signals Growing Confidence in FDA‑Approved Treatment
CEO Nath Kabir’s $5.37 share purchase signals growing confidence in Compass Pathways’ psilocybin future, hinting at upside if FDA approves COMP360.
3 minutes to read